Navigation Links
Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
Date:10/21/2010

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics.

Under the agreement, Algeta has an option to the exclusive rights to incorporate Lumi4® isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

Algeta has proprietary technology relating to the use of the alpha emitter thorium-227 to protein/peptides to target specific cancer cells. Thorium-227 is an isotope that emits high-energy alpha particles. Such isotopes are of considerable interest in the treatment of cancer as they are potent at killing tumor cells but have a highly localized effect. By linking thorium-227 to tumor-targeting molecules such as monoclonal antibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals designed to specifically seek and destroy cancers while minimizing damage to surrounding healthy tissues. "Using Lumi4® bifunctional chelates," explained Thomas Ramdahl, Chief Technology Officer of Algeta, "could create a new class of radioimmunotherapeutics. By linking thorium-227 to selected tumor targeting antibodies using existing non-proprietary chelates , Algeta has already demonstrated in vivo the potential of its proprietary technology for enhancing the performance of radio-immunotherapies based on existing clinical antibodies. We believe that the new chelators will provide even better results."

Lumi4® complexes are a new class of metal lanthanide and actinide chelators based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley and modified by Lumiphore. This unique patent family is focused on a novel cage structure surrounding lanthanide ions which enables them to be tightly held and covalently attached to receptor targeting molecules.

This is the fourth major agreement reached by Lumiphore in the past four years. Previous partnerships include Thermo Fisher Scientific Specialty Diagnostics (www.thermofisher.com) for certain diagnostic tests to be used in both in laboratories and point-of-care-formats including Downs Syndrome; Cis Bio International (www.htrf.com/company/partners/) for the drug discovery research market; and Biophor Diagnostics Inc. (www.biophor.com) for diagnostic tests for drugs of abuse.

About Lumiphore, Inc.Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, log onto www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc.

About AlgetaAlgeta is a focused oncology company developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.

Algeta's lead product Alpharadin (based on radium-223) is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. Its localized action helps preserve the surrounding healthy tissue thereby limiting side-effects.

The development of bone metastases represents a serious development for cancer patients as they are associated with a dramatic decline in patient health and quality of life, ultimately leading to death. Bone metastases represent a major unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g. prostate, breast and lung.

Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from hormone-refractory (castration-resistant) prostate cancer. Alpharadin is also under investigation in phase II clinical trials as a potential new treatment for bone metastases in endocrine-refractory breast cancer patient, and in a phase I/IIa trial in combination with docetaxel chemotherapy in CRPC patients with bone metastases. 

Algeta also aims to develop a future pipeline of tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227, through selective in-licensing and/or acquiring innovative technologies and tumor-targeting molecules.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA). 

Alpharadin and Algeta are trademarks of Algeta ASA. www.algeta.com Media ContactFor Lumiphore, Inc.For Algeta ASA, Kenneth N. Raymond, Ph.D.

Andrew Kay, CEOPresident and Chairman

+47 2300 6742 / +47 4840 1360 (mob)Lumiphore, Inc.Tel: 1-510-642-7219 / 1-510-486-6145

Oystein Soug, CFOFax: 1-510-486-5283

+47 2300 7984 / +47 9065 6525 (mob)kraymond@lumiphore.comThomas Ramdahl, CTO+47 2300 7985 / +47 9139 1458 (mob)post@algeta.comCitigate Dewe Rogerson (PR Advisor to Algeta)David Dible / Helena Galilee / Mark Swallow+44 (0) 207 638 9571david.dible@citigatedr.co.uk
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
3. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
4. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
5. Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
7. K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
8. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Amgen Announces Webcast of 2010 Third Quarter Financial Results
11. ERT to Announce Third Quarter 2010 Results on November 4, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):